Literature DB >> 3240733

Hyperreactivity of platelets to serotonin (5-hydroxytryptamine) in patients with cardiovascular diseases. Influence of ketanserin, a serotonin S2-receptor antagonist.

J De Crée1, V Roels, H Verhaegen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3240733     DOI： 10.2165/00003495-198800361-00015

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  9 in total

1.  Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease.

Authors:  F Dreyfuss; J Zahavi
Journal:  Atherosclerosis       Date:  1973 Jan-Feb       Impact factor: 5.162

2.  A biphasic response of platelets to serotonin.

Authors:  J G White
Journal:  Scand J Haematol       Date:  1970

3.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

4.  Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.

Authors:  J Mehta
Journal:  JAMA       Date:  1983-05-27       Impact factor: 56.272

5.  Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.

Authors:  F De Clerck; J M Van Nueten
Journal:  Thromb Res       Date:  1982-09-15       Impact factor: 3.944

6.  Platelet aggregates in ischemic heart disease.

Authors:  M B Schwartz; J Hawiger; S Timmons; G C Friesinger
Journal:  Thromb Haemost       Date:  1980-07-15       Impact factor: 5.249

7.  Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.

Authors:  J De Cree; J Leempoels; H Geukens; H Verhaegen
Journal:  Lancet       Date:  1984-10-06       Impact factor: 79.321

Review 8.  Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.

Authors:  P Vanhoutte; A Amery; W Birkenhäger; A Breckenridge; F Bühler; A Distler; J Dormandy; A Doyle; E Frohlich; L Hansson
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

9.  The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.

Authors:  J De Cree; J Leempoels; B Demoen; V Roels; H Verhaegen
Journal:  Agents Actions       Date:  1985-07
  9 in total
  2 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.

Authors:  J S Fleming; J O Buchanan; F D Yocca; L G Iben; M J Antonaccio
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.